https://wikimd.org/index.php?action=history&feed=atom&title=MK-4541MK-4541 - Revision history2026-04-27T02:24:43ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=MK-4541&diff=6427945&oldid=prevPrab: CSV import2025-03-05T06:17:57Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|Experimental drug for prostate cancer treatment}}<br />
{{Drugbox<br />
| verifiedfields = changed<br />
| verifiedrevid = 477002123<br />
| IUPAC_name = (2S)-N-[(2S)-1-[(2S)-2-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-[(2S)-2-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]propanamide<br />
| image = MK-4541.svg<br />
| image2 = <br />
}}<br />
<br />
'''MK-4541''' is an experimental [[androgen receptor]] modulator that has been investigated for its potential use in the treatment of [[prostate cancer]]. It is a nonsteroidal compound that acts as a selective androgen receptor modulator (SARM) and has been shown to have antiandrogenic properties.<br />
<br />
==Mechanism of Action==<br />
MK-4541 functions by binding to the [[androgen receptor]]s in the body, which are proteins that mediate the effects of [[androgens]], such as [[testosterone]]. By modulating these receptors, MK-4541 can inhibit the growth of prostate cancer cells, which often rely on androgens for proliferation. Unlike traditional antiandrogens, MK-4541 is designed to selectively target androgen receptors in prostate tissue, potentially reducing side effects associated with systemic androgen deprivation.<br />
<br />
==Development and Research==<br />
MK-4541 was developed by [[Merck & Co.]], a global healthcare company known for its research in pharmaceuticals. The compound was part of a broader effort to develop novel therapies for [[hormone-sensitive cancers]]. Preclinical studies demonstrated its ability to inhibit tumor growth in animal models of prostate cancer.<br />
<br />
===Clinical Trials===<br />
Although promising in preclinical studies, MK-4541 has not yet advanced to late-stage clinical trials. Early-phase trials focused on assessing its safety, tolerability, and pharmacokinetics in humans. The results indicated that MK-4541 was well-tolerated, but further studies are needed to fully understand its efficacy and potential as a therapeutic agent.<br />
<br />
==Potential Benefits==<br />
The selective action of MK-4541 on androgen receptors offers potential benefits over traditional [[androgen deprivation therapy]] (ADT), which can lead to significant side effects such as [[osteoporosis]], [[muscle wasting]], and [[cardiovascular disease]]. By selectively targeting prostate tissue, MK-4541 aims to minimize these adverse effects while effectively managing cancer progression.<br />
<br />
==Challenges and Future Directions==<br />
The development of MK-4541 faces several challenges, including the need for comprehensive clinical trials to establish its efficacy and safety profile. Additionally, the complexity of prostate cancer biology necessitates a thorough understanding of how MK-4541 interacts with other signaling pathways involved in cancer progression.<br />
<br />
Future research may explore combination therapies involving MK-4541 and other anticancer agents to enhance treatment outcomes. The ongoing search for biomarkers to predict response to therapy could also play a crucial role in the personalized treatment of prostate cancer using MK-4541.<br />
<br />
==Related Pages==<br />
* [[Prostate cancer]]<br />
* [[Androgen receptor]]<br />
* [[Selective androgen receptor modulator]]<br />
* [[Androgen deprivation therapy]]<br />
<br />
[[Category:Experimental cancer drugs]]<br />
[[Category:Selective androgen receptor modulators]]</div>Prab